Objective-Accumulating experimental evidence implicates ␤-catenin signaling and enzyme transglutaminase 2 (TG2) in the progression of vascular calcification, and our previous studies have shown that TG2 can activate ␤-catenin signaling in vascular smooth muscle cells (VSMCs). Here we investigated the role of the TG2/␤-catenin signaling axis in vascular calcification induced by warfarin. Methods and Results-Warfarin-induced calcification in rat A10 VSMCs is associated with the activation of ␤-catenin signaling and is independent of oxidative stress. The canonical ␤-catenin inhibitor Dkk1, but not the Wnt antagonist Wif-1, prevents warfarin-induced activation of ␤-catenin, calcification, and osteogenic transdifferentiation in VSMCs. TG2 expression and activity are increased in warfarin-treated cells, in contrast to canonical Wnt ligands. Vascular cells with genetically or pharmacologically reduced TG2 activity fail to activate ␤-catenin in response to warfarin. Moreover, warfarin-induced calcification is significantly reduced on the background of attenuated TG2 both in vitro and in vivo. Conclusion-TG2 is a critical mediator of warfarin-induced vascular calcification that acts through the activation of ␤-catenin signaling in VSMCs. Inhibition of canonical ␤-catenin pathway or TG2 activity prevents warfarin-regulated calcification, identifying the TG2/␤-catenin axis as a novel therapeutic target in vascular calcification. (Arterioscler Thromb Vasc Biol. 2012;32:123-130.)
M edial arterial calcification is common in patients with chronic kidney disease and diabetes mellitus. It leads to arterial stiffening and thus contributes to the development of hypertension. One of the major risk factors for vascular calcification, especially in the setting of uremia and hyperphosphatemia, is warfarin, a staple in anticoagulant therapy administered as a long-term treatment to millions of people. Warfarin treatment correlates with cardiovascular calcification in human patients [1] [2] [3] [4] and causes rapid and extensive medial calcification in animal models. [5] [6] [7] Molecular mechanisms of warfarin-induced calcification are emerging. Warfarin inactivates several regulators of tissue calcification, including matrix Gla protein (MGP) 8 and growth arrestspecific gene 6 protein, 9 through inhibition of their vitamin K-dependent carboxylation. This pharmacodynamic effect of warfarin is based on its chemical similarity to vitamin K. 10 In addition, in a manner similar to vitamin K2, warfarin can directly activate the transcription factor pregnane X receptor, 10 thus affecting the expression of osteogenic genes that are upregulated during the osteoblast-like transformation of calcifying vascular smooth muscle cells (VSMCs). [11] [12] [13] [14] Moreover, warfarin binding can affect protein conformation 15 and may therefore regulate the activities of various other proteins.
Hence, the overall biological effects of warfarin may be mediated by diverse, nonmutually exclusive mechanisms.
Calcifying vascular cells consistently demonstrate signs of osteochondrogenic transdifferentiation, suggesting that similarities exist in molecular regulation between bone development and vascular calcification. Enzyme transglutaminase 2 (TG2) has been identified as a potent regulator of osteochondrogenic differentiation and bone formation. 16 -20 A role for this protein in vascular calcification is suggested by the reported accumulation of either TG2-mediated cross-links or the TG2 protein itself in the calcifying arteries of warfarintreated rats 21 and MGP Ϫ/Ϫ mice. 22 Moreover, experiments using cultured VSMCs and aortic rings have shown that TG2 enhances calcification in elevated inorganic phosphate (Pi), 23, 24 whereas genetic ablation of TG2 prevents this, 24 identifying this enzyme as a key regulator of Pi-induced calcification in vitro, although no mechanistic insights have been specified.
The underlying molecular mechanisms of TG2-mediated calcification remain to be determined; however, our earlier research revealed that TG2 activates ␤-catenin signaling in VSMCs concomitant with increased calcium deposition. 23 ␤-Catenin signaling is a key pathway in osteogenesis 25 that has been implicated in diabetes-associated medial calcification 26 and in valvular calcification. 27 Accretion of the major components of the canonical ␤-catenin signaling pathway, including low-density lipoprotein receptor-related protein 5 (LRP5), Wnt3a, and ␤-catenin protein, suggests activation of this conduit in calcifying heart valves. 27 Activation of ␤-catenin signaling in calcifying medial VSMCs has also been observed in the diabetic model of low-density lipoprotein receptor (LDLR) Ϫ/Ϫ mice, 26 and both calcium accrual and ␤-catenin signaling are inhibited by activation of parathyroid hormone signaling in the vessel walls of these animals. 28 Together, in vitro and in vivo data imply that ␤-catenin activation is a likely mediator of vascular calcification; however, the potential involvement of this signaling in warfarin-induced medial calcification remains elusive. In this study, we demonstrated that canonical ␤-catenin signaling is essential in warfarin-induced vascular calcification. Furthermore, we demonstrated that TG2 is critical for the regulation of both ␤-catenin signaling and warfarin-dependent calcification in VSMCs. Our results support a key role for the TG2/␤-catenin signaling axis in arterial calcification.
Methods
An expanded Methods section is available in the supplemental materials, available online at http://atvb.ahajournals.org.
Animals
Animal used were CB57/B6 and TG2 Ϫ/Ϫ mice (a kind gift from Robert Graham, Victor Chang Cardiovascular Institute, Darlinghurst, New South Wales, Australia). All procedures were approved by the institutional animal care and use committee at the University of Maryland Medical School and were conducted in compliance with National Institutes of Health guidelines for the care and use of laboratory animals. Arterial calcification was induced by a warfarinvitamin K diet following the described protocol. 7
Cell Culture and Calcium Determination
The A10 clonal embryonic rat aortic smooth muscle cell line (A10 VSMC, American Type Culture Collection) was used. Cells were cultured for 6 days in Dulbecco's modified Eagle's medium, 1% FBS, 1.6 mmol/L Pi, and 10 mol/L warfarin (Sigma-Aldrich) unless otherwise stated in the text. Calcium content was determined colorimetrically using the Calcium (CPC) LiquiColor kit (Stanbio) in 0.1 mol/L HCl extracts from cultured cells or aortic tissues.
Oxidative Stress Analysis
Cellular oxidative stress was detected using the cell-permeable fluorogenic probe CellROX (ROX) (5 mol/L; Molecular Probes).
Luciferase Assay
A stable ␤-catenin reporter A10 cell line was established using the CIgnal Lenti transcription factor/lymphoid enhancer binding factor (Tcf/Lef) Luciferase Reporter (SA Biosciences). The luciferase assay (Promega) was performed in a 96-well-plate format and normalized to total lactate dehydrogenase in cell lysates.
TG2 Activity
TG2 activity in total cell lysates was assayed in an ELISA-like assay as previously described 29 by incorporation of biotinylated pentylamine, EZ-link (Pierce), into N,NЈ-dimethylcasein (Sigma-Aldrich). Incorporated EZ-link was detected with ExtrAvidin-Peroxidase (1:5000, Sigma-Aldrich) and Super AquaBlue peroxidase substrate (eBioscience) and measured at 405 nm on a Polarstar Optima plate reader. Purified guinea pig liver TG2 (Sigma-Aldrich) was used as a standard. TG2 activity in live cells was assayed by stable incorpo-ration of the rhodamine-labeled synthetic peptide Pro-Val-Lys-Gly (SY2011) 30 and detected by fluorescence microscopy.
Data Analysis and Statistics
Western blots were analyzed by densitometry using Scion Image (Scion Corp). Real-time polymerase chain reaction and luciferase activity data were quantified using Excel (Microsoft Corp). Results are graphed as meansϮstandard error (SEM). Statistics (t test and ANOVA) were performed using Vassar Stats software (Vassar College, Poughkeepsie, NY). A value of PϽ0.05 was considered statistically significant.
Results

Warfarin Promotes Calcification in Cultured VSMCs
Previous studies have shown that warfarin induces calcification of the elastin-rich arterial wall in vivo and in vitro, suggesting a direct effect of warfarin on vascular tissue. 31 Here, we examined whether warfarin can induce calcification in VSMC cultures that lack the elastic lamellae. High levels of Pi are critical for warfarin-induced ex vivo calcification in aortic rings, 31, 32 and Pi alone is sufficient to induce calcification in cultured VSMCs in a time-and dose-dependent manner in the 1.6 to 3.0 mmol/L range. 33 To allow for the detection of warfarin-induced calcification, we selected relatively low Pi levels to promote moderate calcification, and serum was used at 1% because higher serum levels have been shown to inhibit in vitro calcification. 34 In cultured rat A10 VSMCs, moderate calcification was induced by 1.6 mmol/L Pi in 1% FBS medium (17.7Ϯ6.4 compared with 0.12Ϯ0.03 g Ca 2ϩ /mg protein in normal 1% medium containing Ϸ1 mmol/L Pi, PϽ0.01). This was significantly increased by the addition of 10 mol/L warfarin, up to 62Ϯ15 g Ca 2ϩ /mg protein, PϽ0.01; however, lower levels of Pi, including 1.0 and 1.2 mmol/L, did not support warfarin-induced calcification ( Figure 1A ). This result implies Pi-induced sensitization of VSMCs toward the promineralizing effect of warfarin and thus supports the important role of phosphate in vascular calcification. 31, 33, 35, 36 In addition, warfarin elicited deposition of calcified matrix by VSMCs in a dose-dependent manner ( Figure 1B ), highlighting the specificity of the observed effect.
Because vascular calcification can potently be promoted by oxidative stress, 37 we examined the possibility that warfarin induced oxidative stress in VSMCs. Reactive oxygen species were detected by the incorporation of a fluorogenic probe (ROX) in live A10 VSMCs exposed to either 10 mol/L warfarin or to 100 mol/L menadione (vitamin K3), an oxidative stress inducer used as a positive control. Activation of the ROX probe, resulting in bright red fluorescence, was detected only in the vitamin K3-treated cells ( Figure 1C ). In cells exposed to warfarin, no fluorescence was observed, indicating that warfarin had no oxidative effect on VSMCs. In agreement with this, expression of the oxidative stress markers HIF-1a, Keap-1, and Nrf-2 was not significantly affected by warfarin treatment ( Figure 1D ). These results indicate that warfarin-induced calcification in VSMCs is independent of oxidative stress.
Warfarin Activates ␤-Catenin Signaling in VSMC
Recent studies indicate that warfarin may affect cells via diverse mechanisms, some that involve the inhibition of protein ␥-carboxylation and others that do not. 10 Taking into consideration the proposed role of ␤-catenin signaling in vascular calcification associated with various clinical conditions, 26, 27 we examined the potential involvement of this signaling pathway in warfarin-induced calcification in vitro. ␤-Catenin-dependent luciferase reporter activity showed a significant 2-fold increase in response to warfarin treatment (PϽ0.01) ( Figure 2A ). This activation was specific to warfarin and was not detected in the 1.6 mmol/L Pi medium, which supports moderate calcification (Figure 2A ). To confirm the luciferase reporter results, 3 major hallmarks of ␤-catenin activation were analyzed: accumulation of ␤-catenin protein, its nuclear localization, and transcription of endogenous ␤-catenin target genes. Under promineralizing conditions, warfarin-induced a 2-fold increase in total ␤-catenin protein (PϽ0.05) ( Figure 2B ), caused its nuclear translocation ( Figure 2C ), and activated transcription of ␤-catenin target genes, including axin2, cyclin D1, and Tcf4 (PϽ0.01) ( Figure 2D ). Notably, the canonical ␤-catenin activator Wnt3a induced nuclear translocation of ␤-catenin in VSMCs to a similar extent as warfarin ( Figure 2C ), indicating substantial activation of ␤-catenin in our model.
Canonical ␤-Catenin Signaling Is Critical for Warfarin-Induced Calcification
Activation of ␤-catenin through the canonical pathway is mediated by LRP5/6 receptors, whereas secreted Dikkopf proteins (Dkks) act to inhibit this pathway by binding to the LRP5/6 receptors, targeting them for endocytosis. 38 Recombinant Dkk1 prevented the warfarin-induced activation of the ␤-catenin reporter ( Figure 3A ) and the warfarin-dependent increase in calcification in VSMCs ( Figure 3B ), demonstrating a critical role for the LRP5/6-mediated canonical pathway in this process. Further, Dkk1 attenuated warfarin-induced activation of osteogenic genes ( Figure 3C ), indicating that canonical ␤-catenin signaling plays a key role in the osteogenic transdifferentiation of calcifying VSMCs. Of note, expression of Msx2 mRNA did not increase with warfarin treatment, suggesting that activation of ␤-catenin in VSMCs was not via Msx2, similar to the minor role for Msx2 noted in the calcifying tunica media of the MGP Ϫ/Ϫ mice 39 and in agreement with activation of Msx2 restricted to adventitia in the diabetic LDLR Ϫ/Ϫ mice. 26 
Warfarin Upregulates TG2 Expression and Activity in VSMC
We next sought to identify endogenous activators of the canonical ␤-catenin pathway that may mediate the effect of warfarin. mRNA levels of 4 endogenous canonical Wnt ligands Wnts 2, 3a, 7b, and 8b expressed in cultured 
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VSMCs 40 were not significantly affected by warfarin (Supplemental Figure IA) , and Wif-1, a known antagonist to Wnt ligands, 41 did not mitigate the activation of ␤-catenin or the calcification induced by warfarin (Supplemental Figure IB and ID). Together, these data indicate a Wnt-independent modulation of canonical ␤-catenin signaling induced by warfarin. Enzyme TG2 has been shown in our previous work to bind LRP5, activate ␤-catenin signaling, and enhance VSMC calcification induced by chondrocyte-conditioned medium. 23 To examine whether calcification and ␤-catenin activation induced by warfarin can be mediated by TG2, we analyzed TG2 levels and activity in our system. We found that warfarin caused a significant 6.8Ϯ0.4-fold (PϽ0.01) increase in TG2 mRNA levels ( Figure 4A ). This increase in expression was accompanied by a similar elevation in total transamidating activity, evaluated by an enzymatic ELISAlike activity assay measuring pentylamine incorporation into immobilized casein 29 ( Figure 4B ). The dihydroisoxazole TG2 inhibitor, ERW-1069, 42 dramatically attenuated the warfarindependent induction of transamidating activity ( Figure 4B ), suggesting that this increase is almost entirely owing to the TG2 protein. This was confirmed by the analysis of arterial tissues from wild-type and TG2 Ϫ/Ϫ (TG2-knockout) mice, in which several TG isoforms are expressed (Supplemental Figure II ). Although warfarin significantly increased total transamidating activity in VSMCs from the wild-type mouse, this increase was not observed in the TG2 Ϫ/Ϫ cells ( Figure  4C ). Interestingly, in addition to increasing TG2 expression, we found that warfarin activates the TG2 protein. When added to purified TG2 in the enzymatic assay, warfarin increased transamidating activity in a dose-dependent manner ( Figure 4D) . Catalytic cross-linking activity of TG2 is regulated allosterically at the GTP-binding domain, 43 and it is believed to be suppressed both intracellularly and at the cell surface. 19, 44 To further confirm that warfarin increased cellular TG2 activity in VSMCs, cultured cells were exposed to rhodamine-labeled peptide substrate Pro-Val-Lys-Gly (SY2011) 30,45 for 4 hours, followed by an overnight recovery in regular growth medium to allow for exocytosis of unincorporated substrate. Multiple sites of SY2011 incorporation were observed in warfarintreated cells in contrast to vehicle-treated control cells ( Figure  4E ), further confirming induction of TG2 activity by warfarin.
TG2 Activity Is Central in Warfarin-Induced Activation of ␤-Catenin
Our data demonstrate that warfarin increases TG2 levels and activity, and our previous work has shown that elevated TG2 can activate ␤-catenin in VSMCs. 23 We therefore hypothesized that increased TG2 mediates the warfarin-induced activation of ␤-catenin associated with enhanced vascular calcification. To test this hypothesis, we analyzed the effects of TG2 inhibition on the warfarin-mediated activation of ␤-catenin in A10 VSMCs. The dihydroisoxazole TG2 inhibitors attenuated warfarin-induced accumulation of ␤-catenin protein ( Figure 5A ), as well as activation of ␤-catenin transcriptional activity ( Figure 5B and Supplemental Figure  IIIA) . Furthermore, genetic ablation of TG2 prevented the warfarin-dependent increase of ␤-catenin protein in ex vivo cultures of the TG2 Ϫ/Ϫ arterial tissue ( Figure 5C ), whereas exogenous purified TG2 added to the culture medium partially rescued this phenotype by supporting a significant 1.5-fold increase of ␤-catenin levels (PϽ0.01) ( Figure 5C ). At the same time, the wild-type mouse arterial tissue responded to warfarin treatment ex vivo similar to rat VSMCs, with a 2.5-fold increase (PϽ0.01) in the levels of ␤-catenin protein (Supplemental Figure IIIB) . These data confirm the critical role for TG2 in the activation of ␤-catenin signaling by warfarin. Of note, the addition of exogenous purified TG2 had no significant effect on ␤-catenin protein levels in TG2 Ϫ/Ϫ tissue in the absence of warfarin ( Figure 5C , gray bars). Together with the above observation that warfarin increases the activity of TG2 ( Figure 4D ), this strengthens the notion that only catalytically active TG2 enhances vascular ␤-catenin signaling.
TG2 Activity Is Required for Warfarin-Induced Calcification
Lastly, we analyzed whether the increase in catalytic activity of TG2 was required for warfarin-induced calcification. In vitro, the TG2 inhibitor ERW-1069 completely blocked the increase in calcium deposition induced by warfarin ( Figure  6A ) and attenuated activation of osteogenic gene expression by warfarin in VSMCs ( Figure 6B ). Next, to examine the role of TG2 in warfarin-induced calcification in vivo, wild-type and TG2 Ϫ/Ϫ mice were treated for 3 weeks with warfarinvitamin K regimen, 7 at which time point significant calcification (approximately 2 g Ca 2ϩ /mg dry weight) has been reported in rats. 32 The basal levels of arterial calcification in both genotypes are very similar (0.12Ϯ0.005 g Ca 2ϩ /mg dry weight in wild-type aortas versus 0.1Ϯ0.008 g Ca 2ϩ /mg dry weight in the TG2 Ϫ/Ϫ aortas). Warfarin treatment resulted in a massive 18-fold increase in aortic calcification in the wild-type mice (up to 1.8Ϯ0.35 g Ca 2ϩ /mg dry weight) but in a significantly lower 5-fold increase in calcification in the TG2 Ϫ/Ϫ mice (up to 0.69Ϯ0.12 g Ca 2ϩ /mg dry weight) ( Figure 6C, PϽ0.01) . These findings demonstrate the critical role of TG2 in warfarin-induced vascular calcification.
Discussion
This study presents the first direct evidence for the critical role of TG2-mediated activation of the ␤-catenin signaling pathway in warfarin-induced medial calcification. Although under normal physiological condition vascular ␤-catenin signaling is generally inactive, 46 despite the expression of several canonical Wnt ligands in VSMCs, 40 its activation associates with vascular injury and remodeling. 47, 48 Previous studies have implicated the ␤-catenin signaling pathway in vascular calcification 49 based on the reported accumulation of the pathway proteins in calcific valve disease 27 and in diabetic calcifying lesions. 26, 28, 50 In addition, circumstantial evidence for ␤-catenin signaling in medial calcification is provided by the demonstrated abilities of matrix metalloproteinases to activate ␤-catenin 51 and promote calcification associated with elastin degradation. 52, 53 However, the mechanisms regulating the ␤-catenin pathway in valvular and 
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vascular calcification have yet to be characterized, 49, 54 and the contribution of this pathway to calcification has not been demonstrated.
In this study, warfarin-induced calcification and osteogenic gene expression were studied in cultured aortic smooth muscle (A10) VSMCs, independent of the inflammatory response that commonly accompanies calcification in vivo. Earlier studies investigated inhibition of the ␥-carboxylation pathway by warfarin in cultured VSMCs and in arterial tissue ex vivo. 31, 34 Here, we examined whether other mechanisms relevant to vascular calcification, such as oxidative stress and ␤-catenin signaling, are affected by warfarin and thus may mediate its effect. We did not observe induction of oxidative stress in VSMCs by warfarin, indicating that this mechanism is likely not involved in warfarin-mediated calcification in vitro. However, we did find that warfarin potently activated ␤-catenin signaling. Further, we observed that the LRP5/6 antagonist Dkk1, which has been shown to inhibit osteogenic differentiation in mesenchymal cells and myofibroblasts, 26, 55 attenuated warfarin-induced ␤-catenin activity, expression of osteogenic genes, and calcium deposition in VSMCs. These findings provide novel, direct evidence for the key role of the LRP5/6-mediated canonical ␤-catenin pathway in osteoblastic transformation and calcification in VSMCs and thus expand previous observations implicating ␤-catenin signaling in diverse types of vascular calcification. 49 There is only a limited understanding of endogenous activators of ␤-catenin signaling in vascular calcification in general and in warfarin-induced calcification in particular. Wnts 2, 3a, 7b, and 8b are expressed by VSMCs, 40 and Wnt7b and Wnt3a are increased in the calcifying arteries of the diabetic atherosclerotic LDLR Ϫ/Ϫ mice and in calcified heart valves, 26, 27, 49 indicative of the potential role of these canonical ligands in ␤-catenin activation. However, the levels of these Wnt ligands are not changed in calcification of the MGP Ϫ/Ϫ arteries 39 or during attenuation of ␤-catenin activity and calcification in the LDLR Ϫ/Ϫ mice by parathyroid hormone, 28 and we found that they were also not affected by the calcification-inducing warfarin treatment of VSMCs. Furthermore, warfarin-induced activation of ␤-catenin was not prevented by Wif-1, an antagonist of Wnt ligands. Therefore, other factors responsible for regulation of the canonical ␤-catenin pathway in vascular calcification should be considered.
Here we show that warfarin induces upregulation and activation of TG2, an enzyme that can bind canonical LRP5 receptor, activate ␤-catenin signaling, and enhance phosphate-induced calcification in VSMCs. 23 Using pharmacological and genetic approaches, we show that catalytic activity of TG2 is critical for warfarin-induced activation of ␤-catenin signaling, osteoblast-like transdifferentiation of VSMCs, and calcium mineral deposition in vitro and in vivo, demonstrating the key role for the TG2/␤-catenin axis in warfarin-induced calcification. Moreover, in addition to increased TG2-dependent protein cross-linking in the calcifying aortas of warfarin-treated rats, 21 previous studies showed the requirement for catalytic activity of TG2 in phosphateinduced aortic calcification ex vivo 24 and accumulation of TG2 in arterial walls of the MGP Ϫ/Ϫ mice, 22 indicating that such a mechanism may be involved in diverse variants of medial vascular calcification, although involvement of the ␤-catenin pathway in these cases still needs to be defined. Interestingly, in contrast to medial calcification, in atherosclerotic plaques elevated TG2 is associated with inflammatory cells and acts to regulate plaque stability, showing little correlation with vascular calcification. 56 -59 Thus, biological activities of TG2 may be determined by the local milieu of various regulators that differ between the vascular wall layers.
A plausible model for the warfarin-induced calcification mediated by the TG2/␤-catenin axis is illustrated in Figure 7 . The observed upregulation of TG2 transcript awaits further elucidation. One of the possible mechanisms of this transcriptional activation may be owing to the activation of the nuclear receptor pregnane X receptor (NR1I2) by direct binding of the warfarin molecule. 10 Activated pregnane X receptor may bind to the 4 putative pregnane X receptor-binding sites 60 present in the 4-kb upstream promoter region of the mouse TG2 gene (our unpublished data, 2011). Direct activation of the TG2 catalytic activity by warfarin presents another level of regulation. These effects are specific for TG2, because other transglutaminases expressed in the TG2 Ϫ/Ϫ arteries do not respond to warfarin treatment. The unique feature of the TG2 protein is allosteric inhibition of its catalytic activity, 43 which may be released by the conformational changes on warfarin binding to tyrosine residues (similar to the described interaction of warfarin with the vitamin K epoxide reductase complex subunit 1). 15 Yet another potential pathway, not shown in Figure 7 , may involve inhibition of MGP function by warfarin, leading to accumulation of TG2 in the vessel wall similar to the effect of MGP knockout, 22 but the molecular mechanisms that may underlie this effect are not yet clear. At the next step, upregulated and activated TG2 interacts with LRP5/6 receptors and stimulates canonical ␤-catenin signaling in VSMCs, leading to expression of osteoblastic genes and enhanced calcification.
It is possible that in vivo warfarin may also activate ␤-catenin in VSMCs through enhanced vascular bone morphogenetic protein signaling, which is normally suppressed by ␥-carboxylated MGP protein 61 but may be activated when warfarin inhibits vitamin K-dependent ␥-carboxylation. Although redox cues from immunity and inflammatory cells in the adventitia can also activate the bone morphogenetic protein/Msx2-Wnt signaling in diabetic arteriosclerosis model, 50, 61 in clonal VSMC culture these cells are absent, and warfarin-induced calcification and activation of theTG2/␤catenin axis are not coupled to oxidative stress or changes in Msx2 expression. It is tempting to speculate that the MGPbone morphogenetic protein pathway (which mediates crosstalk between endothelium and VSMCs), 61 the bone morphogenetic protein/Msx2-Wnt cascade originating in the adventitia, 49 and the TG2/␤-catenin signaling axis (which is central for osteogenic transdifferentiation in VSMCs) complement each other to mediate the activation of ␤-catenin and vascular calcification in diverse manifestations of this manifold disorder.
In vitro, warfarin acts as an amplifier rather than inducer of the osteochondrogenic transdifferentiation in VSMCs because it requires elevated levels of Pi. The critical role of increased serum phosphate in vascular calcification is thoroughly supported by previous reports. 31, 33, 35, 36 A new observation of our study is that warfarin augments destabilization of the VSMC phenotype induced by a modest increase in Pi from 1.2 to 1.6 mmol/L, whereas earlier studies analyzed the effects of warfarin on arterial tissue in 2 to 3.8 mmol/L Pi. 5, 32 Taking into account that each 0.33 mmol/L increase in serum phosphate within the "normal" clinical range increases the likelihood of arterial calcification by 34%, 62 our findings indicate that warfarin-induced vascular calcification may substantially vary in the general population and can pose a significant risk in chronic kidney disease patients even in early stages of the disease.
In conclusion, this study provides the first direct evidence for the requirement of the canonical ␤-catenin pathway in vascular calcification and newly identifies the important role of the TG2/␤-catenin signaling axis in warfarin-induced vascular calcification in VSMCs, adding to the emerging list of pharmacotherapeutic targets in cardiovascular disease.
